Site 'Tertiary' Navigation:

Lipocine to Present at the 30th Annual ROTH Conference

SALT LAKE CITY, March 5, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and Chief Executive Officer, will provide a corporate overview at the 30th Annual ROTH Conference, taking place March 11-13 at the Ritz Carlton Hotel in Laguna Niguel, California.

Lipocine Presentation Details 


Monday, March 12


5:00 p.m. Pacific Time


Ritz Carlton Hotel, Laguna Niguel, Green-Salon 3


 (PRNewsfoto/Lipocine Inc.)

About Lipocine

Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes three development programs TLANDO, LPCN 1111 and LPCN 1107.  TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. TLANDO was well tolerated and met the primary efficacy end-points in Phase 3 testing with twice daily dosing and is currently under FDA review.  LPCN 1111, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing and is currently in Phase 2 testing.  LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth, is currently in Phase 2 testing and has been granted orphan drug designation by the FDA. For more information, please visit


SOURCE Lipocine Inc.

For further information: Morgan Brown, Executive Vice President & Chief Financial Officer, Phone: (801) 994-7383, or Investors: Hans Vitzhum, Phone: (646) 597-6979,